Jan 25 (Reuters) - Alnylam Pharmaceuticals Inc:
* ALNYLAM ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORISATION APPLICATION (MAA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS
* ALNYLAM PHARMACEUTICALS- UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY HAS GRANTED DESIGNATION OF PATISIRAN AS A PROMISING INNOVATIVE MEDICINE Source text for Eikon: Further company coverage:
 